A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

All eyes are on new pills for obesity – and a treatment from Novo Nordisk could be the first to reach patients.

The 25-milligram oral version of the Danish drugmaker's obesity drug Wegovy could win approval by the end of the year. As it waits for regulators to sign off, Novo Nordisk bolstered the case for its experimental pill by releasing new data to underscore its safety and effectiveness at the ObesityWeek scientific conference in Atlanta last week.

"I think that it adds to the evidence base to help health care professionals and patients make further decisions about what may be righ

See Full Page